Ceapro Stock

Ceapro Equity

Delisted

The The Equity of Ceapro (CZO.V) as of Aug 12, 2026 is 27.86 M CAD. In the previous year, The Equity was 32.29 M CAD — a change of -13.73% (lower).

Equity

27.86 MCAD

YoY

-13.73%

Last updated:

In 2026, Ceapro's equity was 27.86 M CAD, a -13.73% increase from the 32.29 M CAD equity in the previous year.

Access this data via the Eulerpool API

Ceapro Stock analysis

What does Ceapro do? Ceapro Inc is an innovative biotechnology company based in Edmonton, Canada. The company was founded in 1997 and has since specialized in the development of natural, biological ingredients from plants. It is listed on the Toronto Stock Exchange and has become a key player in the field of natural-based medicine and cosmetics in recent years. Ceapro's business model is based on the research and production of active compounds from plant-based raw materials. The company employs gentle extraction methods that preserve the effectiveness of the ingredients and enable environmentally friendly production. Ceapro collaborates closely with research and industry to ensure the best possible effectiveness and applicability of its products. The company's products are divided into various segments tailored to the needs of customers. One important segment is medicine, where Ceapro focuses on the development of herbal remedies. The company has already developed some promising products in this area, which can be used, for example, for inflammation, pain, or diabetes. Another important segment of Ceapro is cosmetics, where the company researches and produces natural ingredients for skin and hair care. These products are known for their high effectiveness, tolerability, and environmental friendliness. One of the company's most famous products is Avenanthramide, an ingredient derived from oats that offers anti-aging and anti-inflammatory properties. Ceapro also places special emphasis on the development of digestive-aid ingredients that can be used in the food industry. The company relies on plant enzymes and compounds that help support and relieve the digestive system. The use of natural ingredients ensures high tolerability and usability. Over the course of its history, Ceapro Inc has already won numerous awards and prizes that confirm the high quality of its products and the company's innovative power. For example, the company has been repeatedly honored with the Alberta Venture Fast Growth 50 Award and also received the Environmental Stewardship Award from the Edmonton Chamber of Commerce. Ceapro is not only an innovative biotechnology company specializing in the research and production of plant-based ingredients but also an important player in the fields of medicine and cosmetics. The company employs gentle extraction methods and collaborates closely with research and industry to achieve the best possible effectiveness and applicability. The different products are divided into the segments of medicine, cosmetics, and food and are known for their high effectiveness, tolerability, and environmental friendliness. Ceapro is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Ceapro's Equity

Ceapro's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Ceapro's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Ceapro's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Ceapro's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Ceapro’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Ceapro stock

The Equity of Ceapro is 27.86 M CAD in 2026.

The Equity of Ceapro changed from 32.29 M CAD to 27.86 M CAD, representing a -13.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Ceapro since 2006 – with annual values, charts, and detailed analysis.

The Equity's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Ceapro historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Ceapro

All Key Metrics — Ceapro